NasdaqGS:MYGNBiotechs
Myriad Genetics (MYGN) Stock Sinks As Revenue Reset Deepens Loss Fears
Myriad Genetics came into this earnings print already under pressure, with the stock down sharply over the past quarter. Today’s nearly 47% single day slump indicates that sentiment has cracked further, but the numbers behind that move center on one thing. The headline is a revenue reset in a business that still runs at a loss.
Q2 revenue of US$190.7m fell against last year and management cut full year 2026 sales guidance to US$770m to US$790m, while suspending adjusted earnings guidance. For...